Project Grant RM1DA066198

The National Institute on Drug Abuse awarded Boston Medical Center Corporation $2,066,706 on August 1, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to develop and test systems for integrating pre-exposure prophylaxis (PrEP) prescriptions into hospital inpatient workflows as a HIV prevention strategy for people who use drugs.

The award funds PREP-TALK, a project that addresses the gap between the proven efficacy of PrEP and its confinement to outpatient settings, where people who use drugs often lack engagement with healthcare systems. The recipient will implement and evaluate systematic integration of PrEP into inpatient care across four geographically and demographically diverse hospital sites located in Boston, St. Louis, Chapel Hill, and San Francisco. The project team will deploy academic detailing—an evidence-based educational strategy using trained health professionals to deliver targeted outreach to clinicians—informed by community preferences and optimized through human-centered design to shift PrEP prescribing from a purely outpatient consideration to routine inpatient practice.

The project runs from August 1, 2026, through April 30, 2031, with administrative and operational performance centered in Roxbury, Massachusetts. Work is performed at the four hospital sites nationally. The award is structured as a Project Grant with $2,066,706 obligated.